About Cardea Bio
Cardea Bio is a Healthcare company based in San Diego (United States) founded in 2019 by Brett Goldsmith, and was acquired by Paragraf in May 2023. Digital graphene biosensors are developed using machine learning. Cardea Bio has raised $21.8 million across 4 funding rounds from investors including ARE, Agilent and Paragraf. Cardea Bio has completed 1 acquisition, including Nanosens Innovations. Its focus areas include Life Sciences, Life Sciences Platforms and Tools, Instruments and Biosensors. Its competitors include Hememics Biotechnologies, Nix and Monod; 3 of its 3 listed competitors have raised funding.
Company details
Cardea Bio was founded in 2019 in San Diego, United States. Digital graphene biosensors are created through integration of machine learning. Biology-gated transistors, based on patented Field Effect Biosensing technology, form the core products. Chipsets such as CRISPR-Chip are manufactured using this approach. Molecular biology, graphene, nano-physics, electronics, software, and AI are combined in the platform to enable signal detection systems.
Apps and channels of Cardea Bio
its YouTube channel Paragraf has 126 subscribers and 10 videos.
Videos from Cardea Bio
The most watched videos on Cardea Bio's YouTube channel, Paragraf (126 subscribers). Click a video to play it here.
More on Paragraf.
Funding Insights of Cardea Bio
Cardea Bio has successfully raised a total of $21.8M across 4 strategic funding rounds. The most recent funding activity was a Grant round of $1.1 million completed in May 2022. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $21.8M
- Total Rounds 4
- Last Round Grant — $1.1M
- First Round $7.8M
(Mar 2019)
- Investors Count 9
All 4 funding rounds of Cardea Bio with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| May 2022 | $1.1M | Grant | – | – | |
| Jan 2021 | $6.5M | Series A | – | 3E Bioventures Capital | – |
| Sep 2020 | $7.5M | Series A | – | Serra Ventures, Agilent | – |
| Mar 2019 | $7.8M | Series A | – | Alexandria |
10 investors in total: 10 institutional.
Investors in Cardea Bio
Cardea Bio has secured backing from 10 investors, including institutional and venture fund investors. Prominent investors backing the company include ARE, Agilent and Paragraf.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Tech & Life Science focused early & growth stage VC firm investing in the US & China | 3ebiovc.com | Beijing, China | ||
Venture capital fund focused on Agtech and multiple sectors | serraventures.com | Champaign, United States | ||
| tablemountaincapital.com | ||||
| photonfund.cn | ||||
Investments in tech startups are made by Taihill Venture. | taihill.vc | Cambridge, United States | ||
Venture capital fund focused on pre-seed tech startups | foothill.ventures | Los Altos, United States | ||
Charitable foundation investments on poverty reduction and healthcare | 2000 | gatesfoundation.org | Seattle, United States | |
Diversified instruments are developed for scientific and laboratory management. | 1995 | agilent.com | Santa Clara, United States | |
REIT that invests in campuses, multi-tenant spaces and build-to-suit facilities in the US | 1994 | are.com | Pasadena, United States | |
Graphene-based magnetic sensors are developed using proprietary processes. | 2015 | paragraf.com | Peterborough, United Kingdom |
Investor details for Cardea Bio
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of Cardea Bio
17 people are tracked at Cardea Bio (5 in leadership, 10 in board & advisors, 2 in team).
| Name | Role | Group |
|---|---|---|
Brett Goldsmith | Co-Founder & CTO | Leadership |
Kelly Huang | COO | Leadership |
Cris Andersen, CPA | Controller & Director of Finance | Leadership |
Thomas Hermann | Senior Director, Manufacturing and Supply Chain | Leadership |
Michael Catania | Senior Director, Multiomics Assay Development | Leadership |
Tim Hoerr | Board Member | Board & advisors |
Paul Grint | Executive Chairman | Board & advisors |
Biao He | Board Member | Board & advisors |
Dawn Barry | Board Member | Board & advisors |
Sue Wessler | Council Member | Board & advisors |
Virginijus Siksnys | Council Member | Board & advisors |
Phil Cotter | Council Member | Board & advisors |
Elia Stupka | Council Member | Board & advisors |
Kurt Petersen | Council Member | Board & advisors |
Seth Lowry | Board Member | Board & advisors |
Deependra Kumar Ban | Innovation Consultant | Team |
Carmen Sainz Ross | Manager Supply Chain | Team |
Complete people profiles for Cardea Bio
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Cardea Bio
Cardea Bio has strategically engaged in corporate development activities, having acquired 1 company. Notable acquisitions include Nanosens Innovations.
| Company Name | Description | Domain | Location | Founded | Acquired | Amount |
|---|---|---|---|---|---|---|
Nanosize biosensors are developed for biological sample analysis. | nanosens.com | San Diego, United States | 2006 | Oct 2019 | •••• |
Complete acquisition details for Cardea Bio
Acquired stakes, deal sources and the complete acquisition history require an active premium plan.
- Acquired stakes
- Deal sources
- Complete history
- Exports
Verified entity values are shown only after access is granted.
Timeline of Cardea Bio
5 dated milestones of Cardea Bio across 4 years, from founding to its latest funding, stage changes and deals.
- Founded Cardea Bio is founded.
- Funding First funding round of $7.8M.
- Acquisition Acquires Nanosens Innovations.
- Funding Latest funding round, Grant, of $1.1M.
- Exit Acquired by Paragraf.
Competitors of Cardea Bio
Cardea Bio has 3 listed competitors in our database, 3 of them funded. They include Hememics Biotechnologies, Nix and Monod.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| hememics.com | 2009 | Gaithersburg, United States | $4.6M | 13 | Biopreservation platform for mammalian cells and biologics is developed. | |
| nixbiosensors.com | 2015 | Boston, United States | $6.95M | Sweat-based biosensors are provided for body hydration monitoring. | ||
| monod.bio | 2021 | Seattle, United States | $25M | Developer of biosensors to detect viral proteins, toxins, antibodies, and other molecules |
Detailed competitors of Cardea Bio
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Top companies in Life Sciences Platforms & Tools
3 companies that operate in the same segment as Cardea Bio (Life Sciences Platforms & Tools) in United States, ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
Medidata is recognized as a leading provider of SaaS solutions for clinical research. | 1999 | New York, New York, United States | USD 41.5 M | |||
AI-based solutions for health management are provided. | 2015 | Dallas, Texas, United States | USD 2.8 B | 1,111 | ||
Real-world health data is provided for research and decisions. | 2012 | Menlo Park, California, United States | USD 259.16 M |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Cardea Bio
Complete news archive for Cardea Bio
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Cardea Bio
Cardea Bio was founded in 2019.
Cardea Bio is headquartered in San Diego, United States. It is registered at San Diego, California, United States.
Cardea Bio is a funded company, having raised a total of $21.8M across 4 funding rounds to date. The company's 1st funding round was a Series A of $7.8M, raised on Mar 2019.
Cardea Bio was founded in 2019 in San Diego, United States. Digital graphene biosensors are created through integration of machine learning. Biology-gated transistors, based on patented Field Effect Biosensing technology, form the core products. Chipsets such as CRISPR-Chip are manufactured using this approach. Molecular biology, graphene, nano-physics, electronics, software, and AI are combined in the platform to enable signal detection systems.
Cardea Bio's top competitors include Nix, Monod and Hememics Biotechnologies.
Cardea Bio has made 1 acquisition, including Nanosens Innovations.
Cardea Bio has 10 investors. Key investors include ARE, Agilent, Paragraf, Gates Foundation, and 3E Bioventures Capital.
Yes. Cardea Bio was acquired by Paragraf in May 2023.